Last reviewed · How we verify
NCT00126451
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
Phase 2 trial testing MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) in Breast Cancer in 16 participants. Terminated before completion.
11 October 2005
Quick facts
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 1 December 2004 |
| Primary completion | 11 October 2005 |
| Estimated completion | 11 October 2005 |
Drugs / interventions tested
- MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) — full drug profile →
- Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Non-small-cell Lung Carcinoma — all drugs for Non-small-cell Lung Carcinoma →
Sponsor
Merck Sharp & Dohme LLC — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an investigational study to determine the response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to oral suberoylanilide hydroxamic acid (SAHA), to evaluate PET as an earlier indicator of response to SAHA as assessed by response evaluation criteria in solid tumours (RECIST) criteria and to evaluate the safety and tolerability of oral suberoylanilide hydroxamic acid.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Regulated cell death (RCD) in cancer: key pathways and targeted therapies.
Peng F, Liao M, Qin R, Zhu S, et al · · 2022 · cited 586× · PMID 35963853 · DOI 10.1038/s41392-022-01110-y -
Trials with 'epigenetic' drugs: an update.
Nebbioso A, Carafa V, Benedetti R, Altucci L. · · 2012 · cited 162× · PMID 23103179 · DOI 10.1016/j.molonc.2012.09.004 -
Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets.
Bajbouj K, Al-Ali A, Ramakrishnan RK, Saber-Ayad M, et al · · 2021 · cited 121× · PMID 34769131 · DOI 10.3390/ijms222111701 -
Vorinostat (SAHA) and Breast Cancer: An Overview.
Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, et al · · 2021 · cited 73× · PMID 34572928 · DOI 10.3390/cancers13184700 -
Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives.
Buocikova V, Rios-Mondragon I, Pilalis E, Chatziioannou A, et al · · 2020 · cited 42× · PMID 33287297 · DOI 10.3390/cancers12123622 -
Colon Cancer Progression Is Reflected to Monotonic Differentiation in Gene Expression and Pathway Deregulation Facilitating Stage-specific Drug Repurposing.
Bourdakou MM, Spyrou GM, Kolios G. · · 2021 · cited 5× · PMID 34697067 · DOI 10.21873/cgp.20295 -
CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
Han XL, Du J, Zheng YD, Dai JJ, et al · · 2021 · cited 5× · PMID 33959656 · DOI 10.1155/2021/5089371
Verify or expand the search:
- PubMed search for NCT00126451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Merck Sharp & Dohme LLC trials
Trials by the same sponsor.
- NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
- NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
- NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00126451 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
- Last refreshed: 10 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00126451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing